tbuckley/cabot-search huggingface dataset:
Efficacy of ifosfamide, carboplatin and etoposide (ICE) with or without paclitaxel in the second-line treatment of advanced or relapsed bone and soft tissue sarcomas
Authors: I. Kudawara, M. Aono, K. Ohzono, M. Ieguchi, Y. Aoki, A. Matsumine
Journal: Journal of Clinical Oncology (2005)

9075 Background: It is difficult to treat successfully advanced or relapsed bone and soft tissue sarcomas. Ifosfamide, carboplatin and etoposide (ICE) have been shown to be efficacious in chemotherapy for advanced solid tumors. The purpose of this study was to determine the efficacy and feasibility of ICE with or without paclitaxel in advanced or relapsed sarcoma patients. Methods: From 1999 to 2004, 18 patients (pts) with advanced or relapsed bone and soft tissue sarcomas received ICE (ifosfamide 6–15 g/m2, carboplatin 300–500 mg/m2, etoposide 300 mg/m2) in two institutes. 3 pts also received paclitaxel (100–160 mg/m2). Of the 18 pts, 15 had been previously treated with first line chemotherapy including ifosfamide, doxorubicin, and cis-platinum. There were 13 males and 5 females. The median age was 27 (range 6 -76). Tumor locations: extremity in 12 and trunk in 6. Histological diagnoses were osteosarcoma in 3, Ewing tumor in 5, extraskeletal osteosarcoma in 3, leiomyosarcoma in 2 and other high-grade sarcomas in 5. There were 4 with local relapse, 11 with systemic relapse, and 3 at an advanced stage. Results: The overall response rate was 39%: 2 CR, 4 PR,1 MR, 5 SD, and 6 PD. The responses with paclitaxcel were 2 PR and 1 SD. A median 2 cycles (range 1–4) of chemotherapy was given. Serious adverse effects were not seen. One case was performed mestasectomy after chemotherapy. With a median follow up of 9 months (range, 1 -36 months), 3 pts showed no evidence of disease, 2 was alive with disease, and 13 had died of disease. Conclusions: ICE with or without paclitaxel is effective and tolerable for advanced or relapsed sarcomas as second line chemotherapy. However, the survival is short in spite of these responses. New treatment strategies are needed. No significant financial relationships to disclose.
Abstract 2951: Do the Benefits of Post-Operative Beta-Blockade Outweigh the Harms in Patients Undergoing Non-Cardiac Surgery?
Authors: Ripple Talati, Kurt Reinhart, C. M White, Jeffrey Kluger, Craig I Coleman
Journal: Circulation (2008)

While studies of post-operative beta-blockers in patients undergoing non-cardiac surgery (NCS) have demonstrated a reduction in patients’ risk for myocardial infarction (MI), more recent studies ha...
Abstract 4412: High Density tagSNP Candidate Gene Analysis Identifies IKs as a Major Modulator of Genetic Susceptibility to Drug Induced Long QT Syndrome
Authors: Stefan Kaab, Moritz F Sinner, Alfred L George, Arthur A Wilde, Connie R Bezzina, Eric Schulze-Bahr, Pascale Guicheney, Nanette H Bishopric, Robert J Myerburg, Jean J Schott, Arne Pfeufer, Martin Hinterseer, Britt M Beckmann, Gerhard Steinbeck, Siegfried Perz, Thomas Meitinger, H. Wichmann, Christie Ingram, Shannon Carter, Kris Norris, Dana C Crawford, Marylyn Ritchie, Dan Roden
Journal: Circulation (2008)
Abstract 3031: Enhanced Vascular Inflammation In Aortic Valve Stenosis Induced By Increased Proinflammatory Microparticles
Authors: Philipp Diehl, Ferenc Nagy, Verena Sossong, Thomas Helbing, Manfred Olschewski, Friedhelm Beyersdorf, Christoph Bode, Martin Moser
Journal: Circulation (2007)
Abstract 2959: TGF-beta Is A Promising Biomarker For Monitoring The Aortic Root Dilatation And Losartan Therapy In Marfan Syndrome
Authors: Peter Matt, Jennifer Habashi, Tammy Holm, Erin Klein, Matt Gamradt, Hans-Reinhard Zerkowski, Thierry Carrel, David Huso, Jennifer Van Eyk, Harry Dietz
Journal: Circulation (2007)

Objectives: Aortic root dilatation is the main cause of morbidity and mortality in Marfan syndrome (MFS), a disorder caused by mutations in the gene encoding fibrillin-1 and consequent dysregulation of TGF-beta signaling. The aim of this study was to discover a serological biomarker for the aortic root dilatation in a mouse model of MFS, that was also responsive to losartan therapy. Methods: Serum samples from mice heterozygous for a fibrillin-1 missense mutation (C1039G/+) and wild-type mice treated with losartan or placebo were obtained at 10 weeks, 6 months and 10 months of age. Total (acid activated) TGF-beta 1 serum concentrations were measured by ELISA. Echo measurements of the aortic root were obtained from a parasternal long axis view at 10 months of age. Results: Mean TGF-beta serum concentrations were higher in C1039G/+ mice compared to wild-type mice (p=0.01; 80.0 ng/ml (n=5) vs. 58.3 ng/ml (n=4) at 10 weeks, 117.4 ng/ml (n=11) vs. 87.0 ng/ml (n=6) at 6 months, 137.5 ng/ml (n=3) vs. 103.0 ng/ml (n=2) at 10 months, respectively). Losartan-treated C1039G/+ mice had significantly lower mean TGF-beta serum levels compared to C1039G/+ mice with placebo (p=0.007; 92.9 ng/ml (n=5) vs. 117.4 ng/ml (n=11) at 6 months, 101.2 ng/ml (n=13) vs. 137.5 ng/ml (n=3) at 10 months, respectively). Mean TGF-beta serum concentrations in losartan-treated C1039G/+ mice and wild-type mice with placebo were not significant different (p=0.3; 92.9 ng/ml (n=5) vs. 87.0 ng/ml (n=6) at 6 months, 101.2 ng/ml (n=13) vs. 103.0 ng/ml (n=2) at 10 months, respectively). Echo analyses revealed significantly smaller mean aortic root diameters in 10 months old wild-type and losartan-treated C1039G/+ mice compared to age-matched C1039G/+ mice with placebo (p=0.001; 1.94 mm (n=2) and 2.06 mm (n=13) vs. 2.4 mm (n=3), respectively). Conclusions: TGF-beta serum levels are higher in C1039G/+ mice compared to wild-type mice. Losartan treatment of C1039G/+ mice reduces TGF-beta serum concentrations and aortic root diameters towards wild-type levels. Serum TGF-beta is a promising biomarker for prognostication and monitoring the therapeutic response to losartan therapy in Marfan syndrome.
Abstract 9547: Tissue Doppler and Strain Imaging Can Facilitate Weaning Decisions in Patients with Evidence of Cardiac Recovery Suring Mechanical Ventricular Support
Authors: Michael Dandel, Thomas Krabatsch, Evgenij Potapov, Alexander Stepanenko, Yuguo Weng, Christoph Knosalla, Hans B Lehmkuhl, Roland Hetzer
Journal: Circulation (2011)

Background: Echocardiographic monitoring of cardiac size and function during “off-pump” trials is the cornerstone for detection of cardiac recovery during mechanical unloading. Parameters such as left ventricular (LV) diameters and LVEF are helpful to predict the outcome after possible LV assist device (LVAD) removal. However, high inter-observer variability and load dependency of EF measurements are important limitations. Because velocity parameters measurable by tissue Doppler and strain imaging are more reliable for estimation of LV function, we assessed their usefulness for evaluation of recovery. Methods: Pulsed-wave tissue Doppler (PW-TD) measurements of systolic wall motion peak velocities (Sm) at the basal posterior wall were performed since 1999 during all “off-pump” trials before LVAD removal and at all follow-up controls of post-weaning cardiac function. Since 2005, 2D strain and strain rate (SR) measurements (radial, circumferential and longitudinal) were also performed before and after LVAD removal. The prospectively collected PW-TD and 2D strain data were evaluated for their usefulness to predict weaning successes. Results: Heart failure (HF) recurrence after LVAD removal occurred in 10 (31.3%) of 32 patients who underwent PW-TD. Longitudinal and radial Sm was lower in these 10 patients than in those with post-weaning cardiac stability (p &lt; 0.01) Stable patients showed Sm &gt; 8 cm/s. Off-pump Sm ≥ 8cm/s showed predictive values between 87 and 90% for 5 year post-weaning stability. Strain and SR measured in 23 patients revealed higher systolic values in patients with post-weaning stability (p &lt; 0.01). In stable patients global systolic strain and SR values were: ≥ 30% and ≥ 0.9/s for radial thickening, ≥ 15% and ≥ 0.8/s for circumferential shortening, ≥ 12% and ≥ 0.65/s for longitudinal shortening, respectively. Sm, strain and SR instability before and early after LVAD removal appeared predictive for post-weaning recurrence of HF. Conclusion: PW-TD and 2D-strain imaging allow distinction between patients with and without the potential to maintain cardiac stability after LVAD removal and can therefore be useful for evaluation of unloading-induced cardiac recovery and also for prognostic assessments before and early after LVAD removal.
Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
Authors: R. Maron, J. J. Vredenburgh, A. Desjardins, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, S. A. Wagner, M. E. Salacz, H. S. Friedman
Journal: Journal of Clinical Oncology (2008)

2074 Background: The survival for patients with recurrent GBM is dismal, with < 10% alive at two years. GBMs are highly vascular tumors. The more vascular endothelial growth factor (VEGF) a GBM contains, the worse the prognosis. An antibody to VEGF improved survival in a xenograft model of GBM. Bevacizumab is a humanized antibody to VEGF and was active against recurrent GBM when combined with irinotecan. Daily temozolomide may overcome resistance to 5-day temozolomide by depleting MGMT. Methods: The trial combined daily temozolomide at 50 mg/m2/day with bevacizumab at 10 mg/kg every 14 days for patients with recurrent GBM. Thirty-two patients with recurrent GBM were enrolled between 07/18/07–09/02/07, all had received radiation therapy and 20/32 (63%) progressed to 5-day temozolomide. Results: The treatment had acceptable toxicity with one patient with grade 4 hemorrhagic pancreatitis, and one patient with grade 5 pneumocystis carinii pneumonia. There was no > grade 3 hematologic toxicity, and no CNS hemorrhages. Twelve patients (37.5%) had a partial response, another 12 (37.5%) had stable disease, and 8/32 (25%) had progressive disease. Eighteen of the 32 patients remain on study. Two patients requested to come off study secondary to fatigue. Conclusions: Daily temozolomide and bevacizumab is an active regimen against recurrent GBM and has acceptable toxicity. Daily temozolomide is a good platform for combination regimens. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech Genentech Genentech Genentech
Comparison of methods of estimating coronary risk
Authors: E. J Wallis
Journal: BMJ (2000)

Editor—Isles et al have compared the Sheffield, New Zealand, and joint British methods for estimating risk of coronary heart disease.1 But they used an earlier version of the Sheffield table and not the current table, published in the same issue of the journal.2

Earlier versions of the Sheffield table included left ventricular hypertrophy on electrocardiography as a principle risk factor, but this proved too complex for many general practitioners (and, presumably, practice nurses). Could the authors confirm that the Sheffield table they studied included left ventricular hypertrophy and that the other methods compared with it did not, and would they comment on how this may have influenced the preferences expressed?

Their conclusions on the accuracy of the three methods differ from other data available. In our study (in preparation) the Sheffield and joint British methods proved similarly accurate in their measurement of coronary risk, but the New Zealand chart was much less accurate (table). The Sheffield table was even slightly more accurate than the New Zealand chart for estimating cardiovascular rather than coronary risk (table). We are aware of two unpublished, large, independent studies in different patient populations that confirm the lesser accuracy of the New Zealand chart but similar accuracy for the Sheffield and joint British methods. 

Given the lower accuracy of the New Zealand chart and the fact that it estimates five year cardiovascular risk whereas British and European guidelines are expressed in terms of 10 year coronary risk, the New Zealand chart is no longer suitable for use in Britain or the rest of Europe. More suitable paper based options for implementing recent British guidelines are the new Sheffield table2 and the joint British chart,3 which have similar accuracy. When choosing between these it is important to remember that the joint British chart is a risk assessment method and nothing more. The new Sheffield table is a risk assessment method and an accurate screening tool and provides a summary of current guidelines on a single page.
Malignant Transformation of Hepatocellular Adenoma: How Frequently Does It Happen?
Authors: M Kudo
Journal: Liver Cancer (2014)

Hepatocellular adenoma is a very rare disease in Japan, and institutions encounter only a limited number of cases. This is one of the reasons for the current skepticism in Japan over whether hepatocellular adenoma can truly undergo malignant transformation to hepatocellular carcinoma. However, hepatocellular adenoma is highly prevalent in Western countries, particularly in Europe, and textbooks from these countries have long noted that hepatocellular adenoma carries risks of bleeding and malignant transformation. Most of the cases of hepatocellular carcinoma routinely encountered in Japan occur as a result of chronic liver injury from viral disease, and it is extremely rare to encounter liver cancer that has developed from hepatocellular adenoma in healthy liver. It would be no exaggeration to say that this is almost never seen. Therefore, a survey and literature review was conducted to assess how many cases of hepatocellular adenoma actually undergo malignant transformation in Japan.
Abstract 14714: Impact Of The Differential Diagnosis In Tumor Patients With Neoplastic Or Radiation Induced Pericardial Effusion
Authors: Bernhard Maisch, Heinz Rupp, Volker Ruppert, Sabine Pankuweit
Journal: Circulation (2011)

Background: The differential diagnosis of neoplastic (NE) vs. radiation induced pericardial effusion (RE) in patients with current or previous malignancies has impact on their treatment and prognos...
Abstract 286: Efficacy of Surface-versus Invasive Cooling After Sudden Cardiac Arrest
Authors: Undine Pittl, Alexandra Schratter, Denise Lehmann, Katharina Demmin, Meinhard Mende, Gerhard Schuler, Thorsten Klemm, Holger Thiele
Journal: Circulation (2010)

Purpose: Mild induced hypothermia (MIH) has been shown to improve both survival and neurological outcome in comatose sudden cardiac arrest (SCA)-survivors. MIH has to be applied very early to be ef...
Abstract 15325: New Potent Inhibitor of Necrotic Cell Death: Novel Therapeutic Potential of Necrosis Inhibitor, NecroX Against Myocardial Ischemia-Reperfusion Injury
Authors: Ji-Hyun Kim, Ju-Young Kim, Hyun-Jai Cho, Ji-Yun Seo, Jonghanne Park, Han-Mo Yang, Byung-Hee Oh, Young-Bae Park, Hyo-Soo Kim
Journal: Circulation (2011)

Background: Although reperfusion is essential for salvage of the ischemic myocardium, paradoxically reperfusion itself may cause a wide variety of harmful injury to the myocardium. NecroX is known ...
Lecture Notes on Cardiology
Authors: Huon H. Gray, Keith D. Dawkins, John M. Morgan, Iain A. Simpson
Journal: Annals of Internal Medicine (1991)

Foreword. Acknowledgements. Abbreviations. Chapter 1 Taking a Cardiovascular History. Chapter 2 Examination of the Cardiovascular System. Chapter 3 The Electrocardiogram. Chapter 4 Imaging. Chapter 5 Hypertension. Chapter 6 Coronary Heart Disease. Chapter 7 Thrombosis in Cardiovascular Disease. Chapter 8 The Myocardium. Chapter 9 Heart Failure. Chapter 10 Valvular Heart Disease. Chapter 11 The Endocardium. Chapter 12 The Pericardium. Chapter 13 Electrophysiology. Chapter 14 Cardiopulmonary Resuscitation. Chapter 15 Diseases of the Aorta. Chapter 16 Pulmonary Hypertension and Pulmonary Thromboembolism. Chapter 17 Pregnancy and the Heart. Chapter 18 Congenital Heart Disease. Chapter 19 Heart Disease in the Elderly. Chapter 20 Cardiac Tumours. Chapter 21 Surgery and Anaesthesia. Chapter 22 Cardiology, the Law and Occupation. Appendix. Index
The Good Soldier švejk Syndrome
Authors: Peter Tyrer, Jo Emmanuel, Nicholas Babidge, Nishi Yarger, Maya Ranger, Jaroslav Blahošr
Journal: Journal of the Royal Society of Medicine (2001)

We thank your correspondents for putting flesh on the skeleton we presented in our paper (January 2001, JRSM, pp. 22-25), and for illustrating the extensive knowledge of the Good Soldier Svejk (and Czech culture) among JRSM readers. We are taken to task for regarding Svejk as someone who had at least a forme fruste of psychosis as well as periods of being well, although we did not suggest he was learning-disabled (i.e. an imbecile). John Reed and Andrew Bush free him from any mental abnormality (March 2001, JRSM, pp. 156-157) despite his attraction to lunatic asylums where crawling naked, howling like a jackal, raging and biting were commonplace. However, the lifestyle of the Good Soldier could hardly be regarded as persistently and understandably normal, even in the repressive days of Emperor Franz Josef, and whilst it is comforting to believe that he was always a canny and insightful opponent of those who occupied his country, this belief is on a par with the Laingian dogma that schizophrenia was a ‘normal’ escape from the repressive double-bind of conflicts in family and society. In any case, our humble guess is that Svejk would have much preferred to be regarded as partly mad rather than fully sane and if anyone had given him a cartificate of sanity he would have interpreted it as failure on his part, even if it had been given to him by Tomas Masaryk!
Your Growing Child. A Book of Talks to Parents on Life's Needs.
Authors: Bruce, H. Addington , b.
Journal: JAMA (1928)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Surgically Unresectable and Chemotherapy-Refractory Metastatic Liver Carcinoma: Treatment with Yttrium-90 Microsphere Followed by Assessment with Positron Emission Tomography
Authors: Ching-Yee Oliver Wong
Journal: Liver Cancer (2009)

Detection of metastatic cancer to the liver with positron emission tomography (PET) or computed tomography (CT) usually signifies an ominous sign for patients with colorectal cancer (Fernandez et al., 2004; Arulampalam et al., 2001) and other solid cancers (Silvestri et al., 2003; Eubank et al., 2002). Surgically unresectable and chemotherapy refractory metastatic cancer to the liver often represents an end-stage event. For these patients, a wide variety of local and regional therapies have been developed from the experience of treating hepatocellular carcinoma for the purpose of providing local control of liver tumors while sparing essential vascular structures, liver parenchyma, and adjacent organs (Rilling and Drooz, 2002). Yttrium-90 glass and resin micro-spheres have been shown to be chemically durable for in vivo delivery of β-radiation (Drbe and Day, 1993). Recently hepatic intraarterial infusion of Yttrium-90 glass or resin microspheres has been introduced for palliating unresectable hepatocellu-lar carcinoma (Dancey et al., 2000; Ho et al., 1997). Their use in palliation of unresectable liver metastases from solid cancers has been shown to be promising (Wong et al., 2004, 2005). Two commercial products of these microspheres are available in glass matrix (20–30 μm, 3.6 g/ dl, 2,500 Bq/particle, THERA-Sphere®, MDS Nordion, Ottawa, Canada) or resin bound (20–60 μm, 1.6 g/dl, 50 Bq/particle, SIR-Spheres®, Sirtex Medical, New South Wales, Australia) forms (Wong et al., 2006). Both the glass or resin microspheres are introduced via catheterization of the hepatic artery that supplies the majority of the blood. Tumors and the microspheres are trapped in the tumor capillary bed where they exert a local radio-therapeutic effect. Yttrium-90, a pure beta-emitter with a physical half-life of 64.2 h, decays to stable zirconium-90. The average energy of the beta emissions from the Yttrium-90 is 0.9367 MeV, with an average penetration range of 2.5 mm in tissue (Dancey et al., 2000).
Abstract 4998: Elevated Oxidized Phospholipids on Apolipoprotein B-100 Particles Predict 6-Year Cardiovascular Events in the Epic-Norfolk Study: Potentiation of Risk with Lipoprotein-Associated (Lp-PLA <sub>2</sub> ) and Soluble Phospholipase A2 (sPLA <sub>2</sub> ) Activity
Authors: Sotirios Tsimikas, Ziad Mallat, Philippa J Talmud, John J Kastelein, Nicholas J Wareham, Elizabeth R Miller, Joseph L Witztum, Kay-Tee Khaw, S. M Boekholdt
Journal: Circulation (2008)

Objective: We aimed to assess whether oxidized phospholipids on apoB-100 particles (OxPL/apoB) predict future coronary heart disease (CHD) in the prospective EPIC-Norfolk cohort of apparently healthy men and women aged 45–79 years followed up 1993–2007. Methods and Results: Cases who developed CHD during follow-up were matched to controls who remained free of cardiovascular disease and who matched to cases by sex, age and enrollment time. OxPL/apoB levels were measured with antibody E06 in 905 cases and 1809 controls. Subjects in the highest quartile of OxPL/apoB at entry in the study had significantly higher risk of future CHD events (OR 1.72, 95%CI 1.32–2.24, p&lt;0.0001) compared to those in the lowest quartile. This relationship was present in both men and women and was also observed after adjustment for sex, age, diabetes, smoking, blood pressure, LDL-C, HDL-C and Framingham Risk Score (FRS). The risk of future CHD events was significantly potentiated by elevated activity levels of sPLA 2 and Lp-PLA 2 . Subjects in the highest tertiles of both OxPL/apoB and LpPLA2 (OR 2.22 [1.51–3.27]) or OxPL/apoB and sPLA 2 (OR 4.34 [2.84 – 6.64]) had significantly higher risk of future CHD than subjects in the lowest tertiles (p&lt;0.0001 for both). Area under receiver operating curves revealed significantly increased values by adding OxPL/apoB and sPLA 2 to traditional risk factors and the FRS. Strong inverse associations were noted between the OxPL/apoB and VLDL and IDL size, CETP mass and RANK Ligand. Conclusion: Elevated OxPL/apoB levels are a strong, independent predictor of CHD events. The predictive values is further enhanced by elevated activity levels of sPLA 2 and Lp-PLA 2 , which mediate breakdown of OxPL present on lipoproteins and within atherosclerotic lesions. This study links several pathophysiologically related oxidative biomarkers in the prediction of CHD events and suggests novel approaches to predicting CHD risk in apparently health men and women.